17,261 trials
Systemic Lupus Erythematosus
Primary: Cohort A: Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index-A (CLASI-A) Total Score at Week 16 — -5.0; -9.0; -10.2; -9.7 scores on a…
Stroke · Rhabdomyolysis · Jaundice
Primary: Total Number of Participants With an Increase in Liver Function Tests (LFTs) — 1; 2 Participants
Osteosarcoma · Ewing Sarcoma · Rhabdomyosarcoma
Primary: Response Rate — 15.3 percentage of participants
Resectable Esophageal Squamous Cell Carcinoma
Primary: Pathological Complete Response (pCR) Rate — 30.0; 34.4 percentage of participants
Transplant-Associated Thrombotic Microangiopathy
Primary: Pegcetacoplan Pharmacokinetic (PK) Parameter Area Under the Curve Limited to the End of Dosing Interval (AUC0-tau) — 14934.65; 20089.79; 36208.37 µg*h/mL
Salmonella Infections
Primary: Stage 1: Number of Participants With Any Solicited Administration Site Events After the First Study Intervention Administration — 1; 0; 0; 0 Participants
Tetralogy of Fallot · Pulmonary Insufficiency
Primary: Accuracy of 3D Echocardiography Based Measurements of Right Ventricular Size Compared to MRI Derived Values. — 187.1; 175.4; 205.0; 86.0 ml
Glioblastoma, Adult
Primary: Safety and Tolerability of EO2401 Monotherapy, EO2401 in Combination With Nivolumab , EO2401 in Combination With Nivolumab and Bevacizumab — 9; 8; 8 Participants
Advanced Head and Neck Squamous Cell Carcinoma · Advanced Breast Cancer · Advanced Melanoma
Primary: Frequency, and Seriousness of TEAEs — 11; 19; 2; 0 number of events
Ulcerative Colitis
Primary: Reduction From Baseline in Modified Mayo Score (MMS) at Week 8 — -2.9; -3.2; -3.1; -1.9 Score
Hepatitis B, Chronic
Primary: STRIVE and THRIVE: Proportion of Participants Achieving Suppression of HBV DNA (< LLOQ) With HBsAg Loss (< 0.05 IU/mL) at the End of Treatment — 1; 4 Participants
Nonalcoholic Steatohepatitis
Primary: Percentage of Participants Who Achieved ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 72 in Semaglutide (SEMA) +…
Head and Neck Cancer
Primary: Major Pathologic Response (MPR) Rate (Primary (Overall) Analysis) — 7; 10 participants
Pemphigoid, Bullous
Primary: Number of Participants With Anti-Drug Antibodies — 0 Participants
Smoking Cessation · Electronic Cigarette Use · Cigarette Smoking
Primary: Days of Dual Use Abstinence — 3.8; 11.2; 6.9; 4.6 Days